The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis

Jeffery J. Auletta; Amelia M. Bartholomew; Richard T. Maziarz; Robert J. Deans; Robert H. Miller; Hillard M. Lazarus; Jeffrey A. Cohen

doi:10.2217/imt.12.41

The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis

Jeffery J. Auletta, Amelia M. Bartholomew, Richard T. Maziarz, Robert J. Deans, Robert H. Miller, Hillard M. Lazarus, Jeffrey A. Cohen

Knight Cancer Institute

Research output: Contribution to journal › Review article › peer-review

50 Scopus citations

Abstract

Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the CNS for which only partially effective therapies exist. Intense research defining the underlying immune pathophysiology is advancing both the understanding of MS as well as revealing potential targets for disease intervention. Mesenchymal stromal cell (MSC) therapy has the potential to modulate aberrant immune responses causing demyelination and axonal injury associated with MS, as well as to repair and restore damaged CNS tissue and cells. This article reviews the pathophysiology underlying MS, as well as providing a cutting-edge perspective into the field of MSC therapy based upon the experience of authors intrinsically involved in MS and MSC basic and translational science research.

Original language	English (US)
Pages (from-to)	529-547
Number of pages	19
Journal	Immunotherapy
Volume	4
Issue number	5
DOIs	https://doi.org/10.2217/imt.12.41
State	Published - May 2012

Keywords

IFN-γ
Th17 cell
Toll-like receptor
experimental autoimmune encephalomyelitis
immunomodulation
inflammation
mesenchymal stromal cell
multiple sclerosis
transplantation

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.2217/imt.12.41

Cite this

@article{cd4bc2d2755040f48fd1a3e8962623e8,

title = "The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis",

abstract = "Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the CNS for which only partially effective therapies exist. Intense research defining the underlying immune pathophysiology is advancing both the understanding of MS as well as revealing potential targets for disease intervention. Mesenchymal stromal cell (MSC) therapy has the potential to modulate aberrant immune responses causing demyelination and axonal injury associated with MS, as well as to repair and restore damaged CNS tissue and cells. This article reviews the pathophysiology underlying MS, as well as providing a cutting-edge perspective into the field of MSC therapy based upon the experience of authors intrinsically involved in MS and MSC basic and translational science research.",

keywords = "IFN-γ, Th17 cell, Toll-like receptor, experimental autoimmune encephalomyelitis, immunomodulation, inflammation, mesenchymal stromal cell, multiple sclerosis, transplantation",

author = "Auletta, {Jeffery J.} and Bartholomew, {Amelia M.} and Maziarz, {Richard T.} and Deans, {Robert J.} and Miller, {Robert H.} and Lazarus, {Hillard M.} and Cohen, {Jeffrey A.}",

year = "2012",

month = may,

doi = "10.2217/imt.12.41",

language = "English (US)",

volume = "4",

pages = "529--547",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Future Medicine Ltd.",

number = "5",

}

TY - JOUR

T1 - The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis

AU - Auletta, Jeffery J.

AU - Bartholomew, Amelia M.

AU - Maziarz, Richard T.

AU - Deans, Robert J.

AU - Miller, Robert H.

AU - Lazarus, Hillard M.

AU - Cohen, Jeffrey A.

PY - 2012/5

Y1 - 2012/5

N2 - Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the CNS for which only partially effective therapies exist. Intense research defining the underlying immune pathophysiology is advancing both the understanding of MS as well as revealing potential targets for disease intervention. Mesenchymal stromal cell (MSC) therapy has the potential to modulate aberrant immune responses causing demyelination and axonal injury associated with MS, as well as to repair and restore damaged CNS tissue and cells. This article reviews the pathophysiology underlying MS, as well as providing a cutting-edge perspective into the field of MSC therapy based upon the experience of authors intrinsically involved in MS and MSC basic and translational science research.

AB - Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the CNS for which only partially effective therapies exist. Intense research defining the underlying immune pathophysiology is advancing both the understanding of MS as well as revealing potential targets for disease intervention. Mesenchymal stromal cell (MSC) therapy has the potential to modulate aberrant immune responses causing demyelination and axonal injury associated with MS, as well as to repair and restore damaged CNS tissue and cells. This article reviews the pathophysiology underlying MS, as well as providing a cutting-edge perspective into the field of MSC therapy based upon the experience of authors intrinsically involved in MS and MSC basic and translational science research.

KW - IFN-γ

KW - Th17 cell

KW - Toll-like receptor

KW - experimental autoimmune encephalomyelitis

KW - immunomodulation

KW - inflammation

KW - mesenchymal stromal cell

KW - multiple sclerosis

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=84861677241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861677241&partnerID=8YFLogxK

U2 - 10.2217/imt.12.41

DO - 10.2217/imt.12.41

M3 - Review article

C2 - 22642335

AN - SCOPUS:84861677241

SN - 1750-743X

VL - 4

SP - 529

EP - 547

JO - Immunotherapy

JF - Immunotherapy

IS - 5

ER -

The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this